We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Regulatory Protein Modulates Transmembrane Signals

By Biotechdaily staff writers
Posted on 08 Jul 2002
A regulatory protein called NHERF2 (sodium/hydrogen exchanger regulatory factor 2), a member of the PDZ class of proteins, has been shown to mediate the cell's response to binding of parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP). More...
The study was reported in the June 20, 2002, issue of Nature.

PDZ domains were first identified as regions of sequence homology found in diverse signaling proteins. The name PDZ derives from the first three proteins in which these domains were identified: PSD-95 (a 95 kDa protein involved in signaling at the postsynaptic density), DLG (the Drosophila melanogaster Discs Large protein), and ZO-1 (the zonula occludens 1 protein involved in maintenance of epithelial polarity). PDZ domains function as protein-protein interaction modules. The first identified (and by far the most common) function of PDZ domains is the recognition of specific C-terminal motifs found in partner proteins, most often in the cytoplasmic tails of transmembrane receptors and channels.

Adenylyl cyclase activation is thought to be responsible for most cellular responses to PTH and PTHrP, although many actions appear to be independent of adenylyl cyclase. In the current study, researchers from Johns Hopkins University (Baltimore, MD, USA) and Harvard University (Boston, MA, USA) found that when NHERF2 is present along with the parathyroid hormone receptor, the signal is sent via calcium. If there is no NHERF2, then cAMP is responsible for delivering the message.

"The cell's decision to use calcium or cAMP is important because each generates different responses from its target proteins,” explained Dr. Mark Donowitz, professor of medicine at Johns Hopkins University and co-author of the study. "These results show that at the very earliest stage of cell signaling, called receptor binding, there is a switch that determines what kind of signal will be used. To understand cell signaling, you really have to know the whole system.”




Related Links:
Johns Hopkins University
Harvard University

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.